


Lazertinib

Cat. No.:	HY-109061		
CAS No.:	1903008-80-9		
Molecular Formula:	C ₃₀ H ₃₄ N ₈ O ₃		
Molecular Weight:	554.64		
Target:	EGFR		
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 9 mg/mL (16.23 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.8030 mL	9.0149 mL	18.0297 mL
	5 mM		0.3606 mL	1.8030 mL	3.6059 mL	
	10 mM		0.1803 mL	0.9015 mL	1.8030 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer ^[1] .
IC₅₀ & Target	EGFR ^{T790M}
In Vitro	Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib

targets both T790M mutation and activating EGFR mutations (EGFRm) while sparing wild type^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20220177473A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA